10-Q Filing

GUARDANT HEALTH, INC. CIK: 1576280 Q2 2020

Filing Information

Form Type	10-Q
Accession Number	`0001628280-20-011994`
Period End Date	20200630
Filing Date	20200806
Fiscal Year	2020
Fiscal Period	Q2
XBRL Instance	gh-20200630_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 76 Income Statement 80 Cash Flow Statement 88 Stockholders Equity 56 Comprehensive Income 28

Balance Sheet 76 line items

Line Item	Tag	Value	Unit	Period
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$164.67M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$143.23M	USD	Point-in-time
Short-term marketable securities	`MarketableSecuritiesCurrent`	$379.57M	USD	Point-in-time
Short-term marketable securities	`MarketableSecuritiesCurrent`	$773.16M	USD	Point-in-time
Accounts receivable, net	`AccountsReceivableNetCurrent`	$47.99M	USD	Point-in-time
Accounts receivable, net	`AccountsReceivableNetCurrent`	$41.02M	USD	Point-in-time
Common stock, par value (in usd per share)	`CommonStockParOrStatedValuePerShare`	-	USD	Point-in-time
Inventory	`InventoryNet`	$15.18M	USD	Point-in-time
Common stock, par value (in usd per share)	`CommonStockParOrStatedValuePerShare`	-	USD	Point-in-time
Inventory	`InventoryNet`	$20.35M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$11.39M	USD	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	350.00M	shares	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$11.10M	USD	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	350.00M	shares	Point-in-time
Common stock, shares outstanding (in shares)	`CommonStockSharesOutstanding`	99.31M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$1.01B	USD	Point-in-time
Common stock, shares outstanding (in shares)	`CommonStockSharesOutstanding`	94.26M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$597.36M	USD	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	94.26M	shares	Point-in-time
Long-term marketable securities	`MarketableSecuritiesNoncurrent`	$268.78M	USD	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	99.31M	shares	Point-in-time
Long-term marketable securities	`MarketableSecuritiesNoncurrent`	$146.12M	USD	Point-in-time
Assets	`Assets`	$1.28B	USD	Point-in-time
Assets	`Assets`	$962.53M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$56.99M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$43.67M	USD	Point-in-time
Right-of-use assets	`OperatingLeaseRightOfUseAsset`	$29.14M	USD	Point-in-time
Liabilities	`Liabilities`	$114.54M	USD	Point-in-time
Liabilities	`Liabilities`	$112.55M	USD	Point-in-time
Right-of-use assets	`OperatingLeaseRightOfUseAsset`	$38.50M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$8.52M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$17.15M	USD	Point-in-time
Goodwill	`Goodwill`	$3.29M	USD	Point-in-time
Goodwill	`Goodwill`	$3.29M	USD	Point-in-time
Capitalized license fees	`CapitalizedLicenseFees`	$6.89M	USD	Point-in-time
Capitalized license fees	`CapitalizedLicenseFees`	$55.00K	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$4.88M	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$5.12M	USD	Point-in-time
Total Assets	`Assets`	$1.28B	USD	Point-in-time
Total Assets	`Assets`	$962.53M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$15.98M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$16.20M	USD	Point-in-time
Accrued compensation	`DeferredCompensationLiabilityCurrent`	$18.56M	USD	Point-in-time
Accrued compensation	`DeferredCompensationLiabilityCurrent`	$18.53M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$24.05M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$25.70M	USD	Point-in-time
Deferred revenue	`ContractWithCustomerLiabilityCurrent`	$11.48M	USD	Point-in-time
Deferred revenue	`ContractWithCustomerLiabilityCurrent`	$12.28M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$70.05M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$72.73M	USD	Point-in-time
Long-term operating lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$41.12M	USD	Point-in-time
Long-term operating lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$33.26M	USD	Point-in-time
Obligation related to royalty	`AccruedRoyaltiesNoncurrent`	$6.88M	USD	Point-in-time
Obligation related to royalty	`AccruedRoyaltiesNoncurrent`	-	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$1.38M	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$1.67M	USD	Point-in-time
Total Liabilities	`Liabilities`	$114.54M	USD	Point-in-time
Total Liabilities	`Liabilities`	$112.55M	USD	Point-in-time
Redeemable noncontrolling interest	`RedeemableNoncontrollingInterestEquityCarryingAmount`	$50.40M	USD	Point-in-time
Redeemable noncontrolling interest	`RedeemableNoncontrollingInterestEquityCarryingAmount`	$49.60M	USD	Point-in-time
Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of June 30, 2020 and December 31, 2019; 99,312,237 and 94,261,414 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively	`CommonStockValueOutstanding`	$1.00K	USD	Point-in-time
Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of June 30, 2020 and December 31, 2019; 99,312,237 and 94,261,414 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively	`CommonStockValueOutstanding`	$1.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$1.15B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$1.54B	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$1.11M	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$5.39M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-435.18M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-352.81M	USD	Point-in-time
Total Stockholders Equity	`StockholdersEquity`	$468.13M	USD	Point-in-time
Total Stockholders Equity	`StockholdersEquity`	$785.11M	USD	Point-in-time
Total Stockholders Equity	`StockholdersEquity`	$1.11B	USD	Point-in-time
Total Stockholders Equity	`StockholdersEquity`	$798.39M	USD	Point-in-time
Total Stockholders Equity	`StockholdersEquity`	$815.47M	USD	Point-in-time
Total Stockholders Equity	`StockholdersEquity`	$483.15M	USD	Point-in-time
Total Liabilities, Redeemable Noncontrolling Interest and Stockholders Equity	`LiabilitiesAndStockholdersEquity`	$962.53M	USD	Point-in-time
Total Liabilities, Redeemable Noncontrolling Interest and Stockholders Equity	`LiabilitiesAndStockholdersEquity`	$1.28B	USD	Point-in-time

Income Statement 80 line items

Line Item	Tag	Value	Unit	Period
Precision oncology testing	`RevenuefromPrecisionOncologyTesting`	$50.99M	USD	1 Quarter
Precision oncology testing	`RevenuefromPrecisionOncologyTesting`	$111.24M	USD	2 Qtrs
Precision oncology testing	`RevenuefromPrecisionOncologyTesting`	$42.06M	USD	1 Quarter
Precision oncology testing	`RevenuefromPrecisionOncologyTesting`	$70.90M	USD	2 Qtrs
Development services	`RevenuefromDevelopmentServices`	$22.61M	USD	2 Qtrs
Development services	`RevenuefromDevelopmentServices`	$11.91M	USD	1 Quarter
Development services	`RevenuefromDevelopmentServices`	$19.73M	USD	2 Qtrs
Development services	`RevenuefromDevelopmentServices`	$15.34M	USD	1 Quarter
Total revenue	`Revenues`	$90.63M	USD	2 Qtrs
Total revenue	`Revenues`	$133.84M	USD	2 Qtrs
Total revenue	`Revenues`	$66.33M	USD	1 Quarter
Total revenue	`Revenues`	$53.98M	USD	1 Quarter
Cost of precision oncology testing	`CostsofPrecisionOncologyTesting`	$25.67M	USD	2 Qtrs
Cost of precision oncology testing	`CostsofPrecisionOncologyTesting`	$14.65M	USD	1 Quarter
Cost of precision oncology testing	`CostsofPrecisionOncologyTesting`	$36.00M	USD	2 Qtrs
Cost of precision oncology testing	`CostsofPrecisionOncologyTesting`	$17.81M	USD	1 Quarter
Cost of development services	`CostofDevelopmentServices`	$4.70M	USD	2 Qtrs
Cost of development services	`CostofDevelopmentServices`	$2.18M	USD	1 Quarter
Cost of development services	`CostofDevelopmentServices`	$4.63M	USD	1 Quarter
Cost of development services	`CostofDevelopmentServices`	$6.94M	USD	2 Qtrs
Research and development expense	`ResearchAndDevelopmentExpense`	$36.32M	USD	1 Quarter
Research and development expense	`ResearchAndDevelopmentExpense`	$35.85M	USD	2 Qtrs
Research and development expense	`ResearchAndDevelopmentExpense`	$73.33M	USD	2 Qtrs
Research and development expense	`ResearchAndDevelopmentExpense`	$19.53M	USD	1 Quarter
Sales and marketing expense	`SellingAndMarketingExpense`	$37.25M	USD	2 Qtrs
Sales and marketing expense	`SellingAndMarketingExpense`	$25.02M	USD	1 Quarter
Sales and marketing expense	`SellingAndMarketingExpense`	$19.44M	USD	1 Quarter
Sales and marketing expense	`SellingAndMarketingExpense`	$50.13M	USD	2 Qtrs
General and administrative expense	`GeneralAndAdministrativeExpense`	$56.97M	USD	2 Qtrs
General and administrative expense	`GeneralAndAdministrativeExpense`	$26.10M	USD	2 Qtrs
General and administrative expense	`GeneralAndAdministrativeExpense`	$13.44M	USD	1 Quarter
General and administrative expense	`GeneralAndAdministrativeExpense`	$37.19M	USD	1 Quarter
Total costs and operating expenses	`CostsAndExpenses`	$69.24M	USD	1 Quarter
Total costs and operating expenses	`CostsAndExpenses`	$120.95M	USD	1 Quarter
Total costs and operating expenses	`CostsAndExpenses`	$129.56M	USD	2 Qtrs
Total costs and operating expenses	`CostsAndExpenses`	$223.38M	USD	2 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-15.27M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-54.62M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-38.93M	USD	2 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-89.53M	USD	2 Qtrs
Interest income	`InvestmentIncomeInterest`	$5.58M	USD	2 Qtrs
Interest income	`InvestmentIncomeInterest`	$2.64M	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$3.10M	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$5.96M	USD	2 Qtrs
Interest expense	`InterestExpense`	$22.00K	USD	2 Qtrs
Interest expense	`InterestExpense`	$580.00K	USD	2 Qtrs
Interest expense	`InterestExpense`	$10.00K	USD	1 Quarter
Interest expense	`InterestExpense`	$287.00K	USD	1 Quarter
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$2.29M	USD	1 Quarter
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$-51.00K	USD	1 Quarter
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$2.08M	USD	2 Qtrs
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$96.00K	USD	2 Qtrs
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-81.52M	USD	2 Qtrs
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-33.83M	USD	2 Qtrs
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-49.70M	USD	1 Quarter
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-12.51M	USD	1 Quarter
Provision for (benefit from) income taxes	`IncomeTaxExpenseBenefit`	$-1.18M	USD	2 Qtrs
Provision for (benefit from) income taxes	`IncomeTaxExpenseBenefit`	$-1.21M	USD	1 Quarter
Provision for (benefit from) income taxes	`IncomeTaxExpenseBenefit`	$48.00K	USD	2 Qtrs
Provision for (benefit from) income taxes	`IncomeTaxExpenseBenefit`	$34.00K	USD	1 Quarter
Net loss	`ProfitLoss`	$-81.57M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-49.74M	USD	1 Quarter
Net loss	`ProfitLoss`	$-32.65M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-11.30M	USD	1 Quarter
Adjustment of redeemable noncontrolling interest	`NetIncomeLossAttributableToRedeemableNoncontrollingInterest`	$800.00K	USD	2 Qtrs
Adjustment of redeemable noncontrolling interest	`NetIncomeLossAttributableToRedeemableNoncontrollingInterest`	$300.00K	USD	1 Quarter
Adjustment of redeemable noncontrolling interest	`NetIncomeLossAttributableToRedeemableNoncontrollingInterest`	$4.90M	USD	1 Quarter
Adjustment of redeemable noncontrolling interest	`NetIncomeLossAttributableToRedeemableNoncontrollingInterest`	$5.00M	USD	2 Qtrs
Net loss attributable to Guardant Health, Inc. common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-11.60M	USD	1 Quarter
Net loss attributable to Guardant Health, Inc. common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-82.37M	USD	2 Qtrs
Net loss attributable to Guardant Health, Inc. common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-54.64M	USD	1 Quarter
Net loss attributable to Guardant Health, Inc. common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-37.65M	USD	2 Qtrs
Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted (in usd per share)	`EarningsPerShareBasicAndDiluted`	$-0.87	USD	2 Qtrs
Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted (in usd per share)	`EarningsPerShareBasicAndDiluted`	$-0.13	USD	1 Quarter
Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted (in usd per share)	`EarningsPerShareBasicAndDiluted`	$-0.43	USD	2 Qtrs
Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted (in usd per share)	`EarningsPerShareBasicAndDiluted`	$-0.57	USD	1 Quarter
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted (in shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	95.20M	shares	2 Qtrs
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted (in shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	89.04M	shares	1 Quarter
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted (in shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	87.49M	shares	2 Qtrs
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted (in shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	96.01M	shares	1 Quarter

Cash Flow Statement 88 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-81.57M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-49.74M	USD	1 Quarter
Net loss	`ProfitLoss`	$-32.65M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-11.30M	USD	1 Quarter
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$5.01M	USD	2 Qtrs
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$7.11M	USD	2 Qtrs
Amortization of right-of-use assets	`AmortizationOfRightOfUseAsset`	$1.63M	USD	2 Qtrs
Amortization of right-of-use assets	`AmortizationOfRightOfUseAsset`	$3.39M	USD	2 Qtrs
Charge of in-process research and development costs with no alternative future use	`ChargeOfInProcessResearchAndDevelopment`	$8.50M	USD	2 Qtrs
Charge of in-process research and development costs with no alternative future use	`ChargeOfInProcessResearchAndDevelopment`	-	USD	2 Qtrs
Unrealized translation gains (loss) on obligation related to royalty	`UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty`	-	USD	2 Qtrs
Unrealized translation gains (loss) on obligation related to royalty	`UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty`	$51.00K	USD	2 Qtrs
Re-valuation of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	-	USD	2 Qtrs
Re-valuation of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$-190.00K	USD	2 Qtrs
Non-cash stock-based compensation	`ShareBasedCompensation`	$6.40M	USD	2 Qtrs
Non-cash stock-based compensation	`ShareBasedCompensation`	$32.15M	USD	2 Qtrs
Amortization of premium (discount) on marketable securities	`AccretionAmortizationOfDiscountsAndPremiumsInvestments`	$-1.06M	USD	2 Qtrs
Amortization of premium (discount) on marketable securities	`AccretionAmortizationOfDiscountsAndPremiumsInvestments`	$1.28M	USD	2 Qtrs
Benefit from income tax differences	`IncreaseDecreaseInDeferredIncomeTaxes`	$1.24M	USD	2 Qtrs
Benefit from income tax differences	`IncreaseDecreaseInDeferredIncomeTaxes`	-	USD	2 Qtrs
Others	`OtherOperatingActivitiesCashFlowStatement`	$-19.00K	USD	2 Qtrs
Others	`OtherOperatingActivitiesCashFlowStatement`	-	USD	2 Qtrs
Accounts receivable, net	`IncreaseDecreaseInAccountsReceivable`	$-6.89M	USD	2 Qtrs
Accounts receivable, net	`IncreaseDecreaseInAccountsReceivable`	$-234.00K	USD	2 Qtrs
Inventory	`IncreaseDecreaseInInventories`	$5.17M	USD	2 Qtrs
Inventory	`IncreaseDecreaseInInventories`	$5.04M	USD	2 Qtrs
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-438.00K	USD	2 Qtrs
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-1.12M	USD	2 Qtrs
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$1.13M	USD	2 Qtrs
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$242.00K	USD	2 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-2.48M	USD	2 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$3.41M	USD	2 Qtrs
Accrued compensation	`IncreaseDecreaseInEmployeeRelatedLiabilities`	$-31.00K	USD	2 Qtrs
Accrued compensation	`IncreaseDecreaseInEmployeeRelatedLiabilities`	$701.00K	USD	2 Qtrs
Accrued expenses and other liabilities	`IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities`	$2.94M	USD	2 Qtrs
Accrued expenses and other liabilities	`IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities`	$-1.82M	USD	2 Qtrs
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiabilities`	$-3.88M	USD	2 Qtrs
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiabilities`	$1.44M	USD	2 Qtrs
Deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$-792.00K	USD	2 Qtrs
Deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$358.00K	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-18.14M	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-36.65M	USD	2 Qtrs
Purchases of marketable securities	`PaymentsToAcquireMarketableSecurities`	$465.30M	USD	2 Qtrs
Purchases of marketable securities	`PaymentsToAcquireMarketableSecurities`	$418.84M	USD	2 Qtrs
Maturity of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$129.16M	USD	2 Qtrs
Maturity of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$197.55M	USD	2 Qtrs
Business acquisition, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	-	USD	2 Qtrs
Business acquisition, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$9.77M	USD	2 Qtrs
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$19.11M	USD	2 Qtrs
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$5.75M	USD	2 Qtrs
Purchase of intangible assets	`PaymentsToAcquireIntangibleAssets`	$17.89M	USD	2 Qtrs
Purchase of intangible assets	`PaymentsToAcquireIntangibleAssets`	-	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-305.20M	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-304.75M	USD	2 Qtrs
Payments made on royalty obligations	`PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations`	$151.00K	USD	2 Qtrs
Payments made on royalty obligations	`PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations`	-	USD	2 Qtrs
Payments made on capital lease obligations	`FinanceLeasePrincipalPayments`	$62.00K	USD	2 Qtrs
Payments made on capital lease obligations	`FinanceLeasePrincipalPayments`	$79.00K	USD	2 Qtrs
Proceeds from issuance of common stock upon exercise of stock options	`ProceedsFromStockOptionsExercised`	$3.55M	USD	2 Qtrs
Proceeds from issuance of common stock upon exercise of stock options	`ProceedsFromStockOptionsExercised`	$5.53M	USD	2 Qtrs
Proceeds from issuances of common stock under employee stock purchase plan	`ProceedsFromStockPlans`	$1.93M	USD	2 Qtrs
Proceeds from issuances of common stock under employee stock purchase plan	`ProceedsFromStockPlans`	$3.96M	USD	2 Qtrs
Proceeds from public offering, net of underwriting discounts and commissions	`ProceedsFromIssuanceOfCommonStock`	$355.73M	USD	2 Qtrs
Proceeds from public offering, net of underwriting discounts and commissions	`ProceedsFromIssuanceOfCommonStock`	$350.43M	USD	2 Qtrs
Payment of offering costs related to public offering	`PaymentsOfStockIssuanceCosts`	$369.00K	USD	2 Qtrs
Payment of offering costs related to public offering	`PaymentsOfStockIssuanceCosts`	$326.00K	USD	2 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$362.79M	USD	2 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$357.36M	USD	2 Qtrs
Net effect of foreign exchange rate changes on cash and cash equivalents	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$90.00K	USD	2 Qtrs
Net effect of foreign exchange rate changes on cash and cash equivalents	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$49.00K	USD	2 Qtrs
Net increase in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$21.44M	USD	2 Qtrs
Net increase in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$34.11M	USD	2 Qtrs
Cash and cash equivalentsBeginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$164.67M	USD	Point-in-time
Cash and cash equivalentsBeginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$140.54M	USD	Point-in-time
Cash and cash equivalentsBeginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$174.65M	USD	Point-in-time
Cash and cash equivalentsBeginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$143.23M	USD	Point-in-time
Cash and cash equivalentsEnd of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$164.67M	USD	Point-in-time
Cash and cash equivalentsEnd of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$140.54M	USD	Point-in-time
Cash and cash equivalentsEnd of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$174.65M	USD	Point-in-time
Cash and cash equivalentsEnd of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$143.23M	USD	Point-in-time
Operating lease liabilities arising from obtaining right-of-use assets	`RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability`	$11.37M	USD	2 Qtrs
Operating lease liabilities arising from obtaining right-of-use assets	`RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability`	$1.56M	USD	2 Qtrs
Purchases of property and equipment included in accounts payable and accrued expenses	`CapitalExpendituresIncurredButNotYetPaid`	$3.87M	USD	2 Qtrs
Purchases of property and equipment included in accounts payable and accrued expenses	`CapitalExpendituresIncurredButNotYetPaid`	$5.40M	USD	2 Qtrs
Follow-on public offering issuance costs included in accounts payable and accrued expenses	`OfferingCostsIncurredButNotYetPaid`	$761.00K	USD	2 Qtrs
Follow-on public offering issuance costs included in accounts payable and accrued expenses	`OfferingCostsIncurredButNotYetPaid`	$486.00K	USD	2 Qtrs
Initial fair value of contingent consideration at acquisition date	`BusinessCombinationContingentConsiderationLiability`	$1.14M	USD	Point-in-time
Initial fair value of contingent consideration at acquisition date	`BusinessCombinationContingentConsiderationLiability`	-	USD	Point-in-time

Stockholders Equity 56 line items

Line Item	Tag	Value	Unit	Period
Adjustments to additional paid in capital, stock issued, issuance costs	`AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts`	$1.13M	USD	2 Qtrs
Adjustments to additional paid in capital, stock issued, issuance costs	`AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts`	$1.13M	USD	1 Quarter
Adjustments to additional paid in capital, stock issued, issuance costs	`AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts`	$723.00K	USD	1 Quarter
Adjustments to additional paid in capital, stock issued, issuance costs	`AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts`	$723.00K	USD	2 Qtrs
Adjustment of redeemable noncontrolling interest	`ReclassificationsOfTemporaryToPermanentEquity`	$-300.00K	USD	1 Quarter
Adjustment of redeemable noncontrolling interest	`ReclassificationsOfTemporaryToPermanentEquity`	$-5.00M	USD	2 Qtrs
Adjustment of redeemable noncontrolling interest	`ReclassificationsOfTemporaryToPermanentEquity`	$-4.90M	USD	1 Quarter
Adjustment of redeemable noncontrolling interest	`ReclassificationsOfTemporaryToPermanentEquity`	$-800.00K	USD	2 Qtrs
Beginning balance	`StockholdersEquity`	$468.13M	USD	Point-in-time
Beginning balance	`StockholdersEquity`	$785.11M	USD	Point-in-time
Beginning balance	`StockholdersEquity`	$1.11B	USD	Point-in-time
Beginning balance	`StockholdersEquity`	$798.39M	USD	Point-in-time
Beginning balance	`StockholdersEquity`	$815.47M	USD	Point-in-time
Beginning balance	`StockholdersEquity`	$483.15M	USD	Point-in-time
Issuance of common stock in public offering, net of offering costs (in shares)	`StockIssuedDuringPeriodSharesNewIssues`	4.31M	shares	Point-in-time
Issuance of common stock in public offering, net of offering costs (in shares)	`StockIssuedDuringPeriodSharesNewIssues`	5.17M	shares	Point-in-time
Issuance of common stock in public offering, net of offering costs	`StockIssuedDuringPeriodValueNewIssues`	$354.60M	USD	2 Qtrs
Issuance of common stock in public offering, net of offering costs	`StockIssuedDuringPeriodValueNewIssues`	$349.71M	USD	2 Qtrs
Issuance of common stock in public offering, net of offering costs	`StockIssuedDuringPeriodValueNewIssues`	$354.60M	USD	Point-in-time
Issuance of common stock in public offering, net of offering costs	`StockIssuedDuringPeriodValueNewIssues`	$349.71M	USD	1 Quarter
Issuance of common stock in public offering, net of offering costs	`StockIssuedDuringPeriodValueNewIssues`	$354.60M	USD	1 Quarter
Issuance of common stock in public offering, net of offering costs	`StockIssuedDuringPeriodValueNewIssues`	$349.70M	USD	Point-in-time
Issuance of common stock upon exercise of stock options (in shares)	`StockIssuedDuringPeriodSharesStockOptionsExercised`	654,557.00	shares	2 Qtrs
Issuance of common stock upon exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$3.55M	USD	2 Qtrs
Issuance of common stock upon exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$4.99M	USD	1 Quarter
Issuance of common stock upon exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$2.04M	USD	1 Quarter
Issuance of common stock upon exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$5.53M	USD	2 Qtrs
Vesting of common stock exercised early	`StockIssuedDuringPeriodValueStockOptionsExercisedEarly`	$13.00K	USD	1 Quarter
Vesting of common stock exercised early	`StockIssuedDuringPeriodValueStockOptionsExercisedEarly`	$13.00K	USD	1 Quarter
Vesting of common stock exercised early	`StockIssuedDuringPeriodValueStockOptionsExercisedEarly`	$69.00K	USD	2 Qtrs
Vesting of common stock exercised early	`StockIssuedDuringPeriodValueStockOptionsExercisedEarly`	$26.00K	USD	2 Qtrs
Common stock issued under employee stock purchase plan	`StockIssuedDuringPeriodValueEmployeeStockPurchasePlan`	$3.96M	USD	2 Qtrs
Common stock issued under employee stock purchase plan	`StockIssuedDuringPeriodValueEmployeeStockPurchasePlan`	$3.96M	USD	1 Quarter
Common stock issued under employee stock purchase plan	`StockIssuedDuringPeriodValueEmployeeStockPurchasePlan`	$1.93M	USD	2 Qtrs
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$25.82M	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$6.40M	USD	2 Qtrs
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$3.21M	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$32.15M	USD	2 Qtrs
Other comprehensive loss	`OtherComprehensiveIncomeLossNetOfTax`	$1.01M	USD	1 Quarter
Other comprehensive loss	`OtherComprehensiveIncomeLossNetOfTax`	$1.43M	USD	2 Qtrs
Other comprehensive loss	`OtherComprehensiveIncomeLossNetOfTax`	$4.28M	USD	2 Qtrs
Other comprehensive loss	`OtherComprehensiveIncomeLossNetOfTax`	$-2.31M	USD	1 Quarter
Net loss	`ProfitLoss`	$-81.57M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-49.74M	USD	1 Quarter
Net loss	`ProfitLoss`	$-32.65M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-11.30M	USD	1 Quarter
Ending balance	`StockholdersEquity`	$468.13M	USD	Point-in-time
Ending balance	`StockholdersEquity`	$785.11M	USD	Point-in-time
Ending balance	`StockholdersEquity`	$1.11B	USD	Point-in-time
Ending balance	`StockholdersEquity`	$798.39M	USD	Point-in-time
Ending balance	`StockholdersEquity`	$815.47M	USD	Point-in-time
Ending balance	`StockholdersEquity`	$483.15M	USD	Point-in-time
Adjustments to additional paid in capital, stock issued, issuance costs	`AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts`	$1.13M	USD	2 Qtrs
Adjustments to additional paid in capital, stock issued, issuance costs	`AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts`	$1.13M	USD	1 Quarter
Adjustments to additional paid in capital, stock issued, issuance costs	`AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts`	$723.00K	USD	1 Quarter
Adjustments to additional paid in capital, stock issued, issuance costs	`AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts`	$723.00K	USD	2 Qtrs

Comprehensive Income 28 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-81.57M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-49.74M	USD	1 Quarter
Net loss	`ProfitLoss`	$-32.65M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-11.30M	USD	1 Quarter
Unrealized gain (loss) on available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-2.34M	USD	1 Quarter
Unrealized gain (loss) on available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$1.34M	USD	2 Qtrs
Unrealized gain (loss) on available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$4.23M	USD	2 Qtrs
Unrealized gain (loss) on available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$852.00K	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax`	$159.00K	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax`	$48.00K	USD	2 Qtrs
Foreign currency translation adjustments	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax`	$25.00K	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax`	$90.00K	USD	2 Qtrs
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$1.01M	USD	1 Quarter
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$1.43M	USD	2 Qtrs
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$4.28M	USD	2 Qtrs
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-2.31M	USD	1 Quarter
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-31.22M	USD	2 Qtrs
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-52.05M	USD	1 Quarter
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-77.29M	USD	2 Qtrs
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-10.29M	USD	1 Quarter
Comprehensive loss attributable to redeemable noncontrolling interest	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest`	$4.90M	USD	1 Quarter
Comprehensive loss attributable to redeemable noncontrolling interest	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest`	$5.00M	USD	2 Qtrs
Comprehensive loss attributable to redeemable noncontrolling interest	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest`	$300.00K	USD	1 Quarter
Comprehensive loss attributable to redeemable noncontrolling interest	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest`	$800.00K	USD	2 Qtrs
Comprehensive loss attributable to Guardant Health, Inc.	`ComprehensiveIncomeNetOfTax`	$-10.59M	USD	1 Quarter
Comprehensive loss attributable to Guardant Health, Inc.	`ComprehensiveIncomeNetOfTax`	$-36.22M	USD	2 Qtrs
Comprehensive loss attributable to Guardant Health, Inc.	`ComprehensiveIncomeNetOfTax`	$-56.95M	USD	1 Quarter
Comprehensive loss attributable to Guardant Health, Inc.	`ComprehensiveIncomeNetOfTax`	$-78.09M	USD	2 Qtrs

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.